Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130222:nPnLA64652

THOUSAND OAKS, Calif., Feb. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) notes
that an analysis by the Congressional Budget Office released this week shows
that, contrary to the implications of past media reports, keeping oral-only
drugs in Medicare Part D would actually achieve significant savings over time
for both taxpayers and the Medicare program.

As noted by the Government Accountability Office (GAO), it is important that the
Centers for Medicare and Medicaid Services (CMS) take the time needed to develop
quality metrics and further develop their data systems, both of which are
essential to providing quality care for an elderly and chronically ill patient
population.

Amgen will continue to advocate for sound federal policies that enhance access
to care for these patients.

For more background, please visit Our Perspectives on www.amgen.com.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen